Cite
HARVARD Citation
Petersen, P. et al. (2021). A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma. Acta oncologica. pp. 948-953. [Online].